The stocks of AAL have upgraded their price rating from underperform to “market perform”, courtesy of analysts working at Raymond James. This was then published in a research report on Friday.
The Stock Commentary Of AAL
There have been quite a few research equities that have commented on the stocks of AAL. Jefferies Financial Group has already increased the rating of the company from underperform to hold with a price target that has been increased to $25 in a 30th March research report. The Goldman Sachs Group has also increased the price target to $20, with a rating of neutral in a 16th March research report.
Stifel Nicolaus has increased the price target of the company from $14 to $20, with a rating that has been set at hold in a 24th February research report. Morgan Stanley has also issued a rating of underweight with a price target of $20 on the stocks of the company.
Seven of the investment analysts involved have given a rating of sell, while nine others have put up a rating of hold. Currently, AAL has a hold rating with a $15.80 price target.
The stocks of AAL traded on Friday at $20.07. The market cap of the firm is $12.87 billion, with a -1.45 PE ratio, along with a 1.82 beta. The year low of the company is $8.25, with a year high of $26.09. The moving average price of the company over 50 days is $22.95, with a moving average price over 200 days set at $17.18.
AAL put up its quarterly result on the 22nd of April. The company had an EPS of $4.32 for this quarter, which was more than the consensus estimate of $4.30. The revenue generated by the company during this period was $4.01 billion, which was slightly less than the consensus estimate of $4.04 billion.
